Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

4.3K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

2.0K
2.0K
Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Post-treatment care for breast cancer].

MMW Fortschritte der Medizin·2026
Same author

Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Nature communications·2026
Same author

Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Medical education in Obstetrics and Gynecology: preferences of medical students regarding digital teaching.

Frontiers in medicine·2025
Same author

AXINEO: AXIllary response to NEOadjuvant chemotherapy for breast cancer: can we predict response based on a biomarker panel?

Archives of gynecology and obstetrics·2025
Same journal

Radiomics and Deep Learning: Bridging Breast Cancer Imaging Phenotypes and Genomic Heterogeneity.

Breast cancer (Dove Medical Press)·2026
Same journal

Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation.

Breast cancer (Dove Medical Press)·2026
Same journal

Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer.

Breast cancer (Dove Medical Press)·2026
Same journal

Advancing Germline Genetic Testing for Breast Cancer in Resource-Restricted Settings: Evidence, Barriers, and a Practical Roadmap for Implementation.

Breast cancer (Dove Medical Press)·2026
Same journal

SLC2A9-Mediated Uric Acid Homeostasis Modulates Apoptosis in TNBC.

Breast cancer (Dove Medical Press)·2026
Same journal

Risk Factors and Prognosis Analysis of Infiltrating Micropapillary Carcinoma of Breast: A Retrospective Study.

Breast cancer (Dove Medical Press)·2026
See all related articles

Related Experiment Video

Updated: May 4, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

7.8K

Dormancy in breast cancer.

Malgorzata Banys1, Andreas D Hartkopf2, Natalia Krawczyk2

  • 1Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany ; Department of Obstetrics and Gynecology, Marienkrankenhaus Hamburg, Hamburg, Germany.

Breast Cancer (Dove Medical Press)
|December 25, 2013
PubMed
Summary
This summary is machine-generated.

Tumor dormancy involves dormant cancer cells causing late relapses, especially in breast cancer. Understanding these quiescent cells may lead to new therapies targeting metastasis.

Keywords:
circulating tumor celldisseminated tumor celltargeted therapytumor dormancy

More Related Videos

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
09:14

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

Published on: August 11, 2011

15.1K
A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells
12:48

A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells

Published on: February 16, 2018

7.1K

Related Experiment Videos

Last Updated: May 4, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

7.8K
An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth
09:14

An In Vitro System to Study Tumor Dormancy and the Switch to Metastatic Growth

Published on: August 11, 2011

15.1K
A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells
12:48

A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells

Published on: February 16, 2018

7.1K

Area of Science:

  • Oncology
  • Cancer Biology
  • Translational Medicine

Background:

  • Tumor dormancy is a state of prolonged cancer cell quiescence without apparent disease progression.
  • Breast cancer exhibits long asymptomatic periods (up to 25 years) followed by relapse, highlighting the significance of dormancy.
  • The factors influencing tumor cell entry into, duration of, and exit from dormancy are not fully understood.

Purpose of the Study:

  • To review the biological mechanisms underlying tumor dormancy.
  • To discuss the clinical implications of tumor dormancy in breast cancer.
  • To explore how understanding dormancy can inform targeted therapy development.

Main Methods:

  • Review of current literature on tumor dormancy mechanisms.
  • Analysis of hypotheses regarding dormant cell persistence (cell cycle withdrawal vs. slow proliferation with cell death).
  • Discussion of the potential stem cell-like characteristics of dormant disseminated tumor cells.

Main Results:

  • Dormant tumor cells may survive by withdrawing from the cell cycle or proliferating slowly, balanced by cell death.
  • Disseminated tumor cells in dormancy are hypothesized to possess stem cell-like properties, contributing to long survival and potential chemotherapy resistance.
  • Understanding these mechanisms is crucial for developing therapies against dormant cells.

Conclusions:

  • Tumor dormancy is a critical factor in late cancer relapse, particularly in breast cancer.
  • Dormant tumor cells, potentially with stem cell characteristics, pose a therapeutic challenge due to their resistance.
  • Further research into the biology of tumor dormancy is essential for developing novel strategies to eliminate residual disease and prevent metastasis.